TCR2 Therapeutics
clinical activity at or below | TCR2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
27 of 34
Similar slides by TCR2 Therapeutics
See diffirences between slides (animation)
Results
September 2022
survival in ovarian cancer after infusion | TCR2 Therapeutics
Results
September 2022
consistent tumor regression in patients with | TCR2 Therapeutics
Results
September 2022
phase data support a path forward as leader | TCR2 Therapeutics
Results
September 2022
promising signal in platinum refractory ovarian cancer months months | TCR2 Therapeutics
Related slides by other companies
Erasca
IPO
July 2021
examples of single agent clinical activity of eras responses in melanoma and salivary gland adenocarcinoma pease | Erasca
Aravive
Investor Presentation
September 2022
clinical activity of | Aravive
Aravive
Investor Presentation
September 2022
clinical activity by status | Aravive
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights